Lutathera (Lutetium Lu 177 Dotatate)
Customize your policy alerts
Sign up for blue cross blue shield - south dakota Policy 06.01.38 alerts
Get alerted when Policy 06.01.38 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, dosing regimen, and eligibility criteria for Lutathera in patients with neuroendocrine tumors and select related indications for Blue Cross Blue Shield - South Dakota members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lutathera (Lutetium Lu 177 Dotatate)
Medically Necessary Indications
Lutetium 177 (Lu 177) dotatate is considered medically necessary in patients 12 years and older when ONE of the following indications is met AND all additional requirements are satisfied:
Indication 1 per policy
Indication 2 per policy
Indication 3 per policy
Indication 4 per policy
Indication 5 per policy
See policy guidelines for acceptable imaging modalities
Investigational / Not Medically Necessary
These uses are considered investigational due to insufficient evidence.
Initial Therapy — Lutetium 177 dotatate for GEP-NETs
Covered when ALL of the following are met
Consistent with study selection and FDA‑labeling
Per regulatory and policy requirements
Initial Therapy
Covered when ALL of the following are met:
Derived from trial inclusion criteria and FDA regimen.
Coverage considerations by tumor type
Coverage considerations are informed by clinical context, evidence strength, and prior therapies:
NETTER‑1 and NETTER‑2 form primary RCT evidence for GEP‑NETs
FDA noted limitations in ERASMUS data (missing baseline data, high dropout) that limit interpretability.
Consider available comparators (radiation, ablation, chemoembolization, systemic therapies) and guideline statements when selecting patients.
Coverage considerations — pheochromocytoma/paraganglioma
Evidence and guideline context for Lu 177 dotatate in pheochromocytoma/paraganglioma:
See Prado‑Wohlwend et al and SEPTRALU registry
Outcomes derived from nonrandomized data and meta‑analyses
Safety monitoring advised per policy
Confirm SSTR positivity and adequate organ function
Per the policy, Lutetium Lu 177 dotatate is considered investigational for uses that exceed the FDA-approved total dosing course, for pediatric patients aged ≤17 years, and for any indication not explicitly listed as medically necessary. Specifically, use of the agent at a cumulative total of more than 4 doses or in patients younger than 12 years through 17 years is excluded and may be denied as investigational when the listed medically necessary criteria are not met. These limits align with the FDA‑approved regimen and the policy's investigational statement.
The evidence for Lutetium Lu 177 dotatate in pheochromocytoma and paraganglioma is limited and derived primarily from systematic reviews, single‑arm studies, registries (for example SEPTRALU), and case series rather than randomized controlled trials. The policy notes that before approval of iobenguane I 131, Lu 177 dotatate was used off‑label in this population; available studies report heterogeneous outcomes and do not stratify results by iobenguane (MIBG) uptake status in all cohorts. Guidelines (NCCN) give a category 2A recommendation but emphasize limited data and encourage clinical trial participation for these rare tumor groups.
Many of the nonrandomized data sources are retrospective single‑arm cohorts or registries. The policy emphasizes that such designs, by themselves, are limited evidence for efficacy when there is insufficient documentation tying treated patients to trial‑like eligibility criteria (for example, absence of documented somatostatin receptor positivity, inadequate performance status, or renal function). Single‑arm or registry reports without comparator groups and without trial‑style inclusion/exclusion documentation may therefore be insufficient to support coverage absent additional supporting clinical information.
For bronchopulmonary and thymus neuroendocrine tumors the primary evidence comes from the ERASMUS cohort and retrospective case series. The FDA review identified important limitations: small subgroup sample sizes (e.g., 23 bronchopulmonary and 2 thymus patients in ERASMUS), missing baseline tumor assessments, high dropout rates, and open‑label single‑arm design. These methodological shortcomings limit interpretability of time‑to‑event outcomes (PFS, OS) and therefore constrain the strength of coverage determinations based solely on these data.
No prospective randomized trials directly comparing Lutetium Lu 177 dotatate with iobenguane I 131 in non‑MIBG‑avid pheochromocytoma/paraganglioma were identified. Comparative evidence is therefore lacking, and reported series sometimes include mixed or unstratified iobenguane uptake results. This gap is relevant when considering alternative therapies for MIBG‑avid disease and underscores the need to confirm somatostatin receptor positivity and consider guideline recommendations (including use of iobenguane I 131 for MIBG‑positive patients).
The provided document segment does not contain additional explicit exclusion statements beyond those summarized elsewhere in the policy window. For the full list of exclusions and any additional not‑medically‑necessary statements, reviewers should consult the complete policy text outside this excerpt.
The policy explicitly states that any use that does not meet the listed medically necessary criteria, or that exceeds the approved dosing limits, is considered investigational and not medically necessary. In practice this includes treatments beyond the total of 4 doses specified in the FDA regimen and any indications not enumerated in the medically necessary section; prior authorization and documentation consistent with the policy are required to avoid denial.
There are no data in this segment to support a mandated therapeutic sequence beyond the approved agents. The policy notes that no specific sequence of second‑line therapies is supported by evidence, and that established FDA‑approved agents (for example, streptozocin, everolimus, sunitinib for pancreatic NETs) exist; clinicians should exercise caution when using Lu 177 dotatate outside labeled indications or prior progression on indicated first‑line therapies, and document the clinical rationale.
Use of Lu 177 dotatate for tumors that are not demonstrably somatostatin receptor–positive (for example non‑GEP histologies without evidence of SSTR expression) is unsupported by the available evidence cited in this policy segment. The policy specifically flags use in non‑SSTR‑positive tumors or non‑GEP neuroendocrine histologies without documentation of receptor expression as lacking supportive data and therefore not medically necessary.
The policy requires documented somatostatin receptor expression on appropriate imaging (preferably SSTR‑PET or, if not available, octreotide SPECT) with lesion uptake greater than liver to establish suitability for Lu 177 dotatate. Use of the therapy without such documentation of receptor expression or without supportive imaging evidence is not supported by the studies reviewed and may be considered investigational or may trigger requests for additional documentation.
Within the excerpt provided, explicit statements labeled 'not medically necessary' are limited. The document segment does reiterate that uses not meeting the medically necessary criteria or exceeding dosing thresholds are investigational, but for the full set of specific 'not medically necessary' language and comprehensive exclusions, reviewers should refer to the complete policy outside this window.
Coding and Dosing Information
| No codes listed |
| No codes listed |
| 7.4 GBq (200 mCi) | Lu 177 dotatate administered per dose as reported in trials/registries |
| A9513 | Lutetium Lu 177, Dotatate, therapeutic 1 millicurie (Lutathera). |
| No code(s) | CPT codes not specified in this segment; provider should use appropriate CPT/other billing codes as applicable. |
Prior Authorization, Documentation, and Operational Requirements
Prior Authorization Required
Prior approval is required. Authorization is limited to FDA‑approved indications for Lutathera® (Lutetium Lu 177 Dotatate) — primarily somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) in adults and the FDA‑approved pediatric expansion for ages ≥12 years. Prior authorization will be for the planned treatment course consistent with the FDA‑approved regimen (7.4 GBq [200 mCi] every 8 weeks for a total of 4 doses) and should document the indication and intended dosing schedule.
- Authorization tied to labeled SSTR‑positive GEP‑NETs and pediatric expansion for ≥12 years
- Planned dosing schedule must follow FDA regimen: 7.4 GBq (200 mCi) every 8 weeks × 4 doses
- Prior approval required
Prior Authorization Requirements — Clinical Rationale and Prior Therapies
Requests must include documentation that supports the medical necessity and indication for PRRT. Prior authorization must demonstrate tumor type, prior therapies (including progression despite somatostatin analogues or targeted therapy when applicable), and the clinical rationale for choosing Lutathera over alternative therapies or clinical trial enrollment.
- Document disease progression despite somatostatin analogue therapy or molecularly targeted therapy for GEP‑NETs when relevant
- State prior lines of therapy and why alternatives (e.g., everolimus, temozolomide, hepatic‑directed therapies) are inappropriate or exhausted
- Clinical rationale if using as primary vs subsequent therapy
Verify Indication and Somatostatin Receptor Positivity
Verify the indication and SSTR‑positivity prior to authorization. Provide pathology confirming tumor type and differentiation (including Ki‑67 index) and SSTR‑based imaging that demonstrates uptake in measurable lesions greater than liver uptake. Also supply baseline organ function and performance status information consistent with pivotal trials.
- Pathology report with Ki‑67 index and tumor differentiation (well‑differentiated, Ki‑67 ≤20% for NETTER‑1 population)
- SSTR‑PET (preferred: Ga‑68 dotatate/dotatoc or Cu‑64 dotatate) showing lesion uptake > liver; Octreoscan SPECT/CT acceptable only if PET unavailable
- Baseline labs: adequate bone marrow, renal and hepatic function; creatinine clearance criteria per policy and trial inclusion
- Performance status (e.g., Karnofsky or ECOG) and any trial‑based inclusion criteria
Coding and Reporting — Radiopharmaceutical Billing
Use HCPCS A9513 to report Lutetium Lu 177 dotatate (Lutathera) therapeutic radiopharmaceutical (per millicurie). Claims for radiopharmaceutical services are subject to medical policy review and must include the documentation submitted for prior authorization. Missing or incorrect radiopharmaceutical coding or omission of HCPCS A9513 may result in claim denial.
- HCPCS A9513: Lutetium Lu 177, Dotatate, therapeutic 1 millicurie (Lutathera)
- Ensure radiopharmaceutical billing aligns with submitted prior authorization documentation and policy requirements
- Claims may be reviewed for compliance with dosing limits and course (maximum 4 doses)
Investigational Uses and Denial Triggers
Investigational/unproven uses will be denied. Examples include requests exceeding the FDA‑approved total of 4 doses, use in pediatric patients ≤17 years (except FDA‑approved pediatric indication ≥12 years), any indication that does not meet the stated criteria, or incomplete documentation supporting eligibility.
- Denial risk for >4 total doses
- Use in pediatric patients ≤17 years (unless meeting the April 2024 FDA approval criteria for ≥12 years) is investigational
- Requests missing required eligibility documentation (pathology, SSTR imaging, baseline labs) may be denied
Trial‑Based Inclusion Considerations
Trial‑based inclusion criteria should be considered when assessing eligibility. Patients who do not meet key NETTER trial inclusion criteria (e.g., required performance status, creatinine clearance thresholds, SSTR expression on all lesions) may be ineligible under this policy. Participation in clinical trials is encouraged for rare tumor groups or settings with limited randomized data.
- NETTER‑1/2 inclusion concepts: confirmed SSTR expression on lesions, sufficient performance status, minimum creatinine clearance thresholds
- Patients failing to meet pivotal trial criteria (e.g., creatinine clearance limits, performance status) may not qualify
- Encourage clinical trial enrollment for rare indications (pancreatic NETs, pheochromocytoma/paraganglioma, bronchopulmonary/thymic NETs)
Limitations of Single‑Arm ERASMUS Data
Limitations of single‑arm ERASMUS data should inform authorization decisions for bronchopulmonary or thymic NETs. The FDA identified missing baseline data, high dropout, and open‑label design as reasons time‑to‑event outcomes were less interpretable; these limitations may affect coverage determinations for indications lacking randomized evidence.
- ERASMUS cohort: retrospective data with missing baseline information and high dropout limiting interpretability
- FDA noted caution using single‑arm ERASMUS results to infer efficacy for bronchopulmonary/thymic NETs
- Use of Lutathera in these tumor types should be supported by additional documentation given limited RCT evidence
Required Clinical Documentation for Authorization
Required clinical documentation to support prior authorization includes: pathology confirmation with Ki‑67, SSTR‑based imaging demonstrating uptake > liver, baseline laboratory studies (bone marrow indices, renal function/creatinine clearance, hepatic panel), prior treatment history with dates and responses, performance status, and treating clinician’s rationale including planned dosing schedule and safety monitoring plan.
- Pathology report with Ki‑67 index and tumor differentiation (well‑differentiated)
- SSTR‑PET report (or Octreoscan SPECT/CT if PET unavailable) showing lesion uptake greater than liver
- Baseline labs: CBC with differential, creatinine/creatinine clearance (Cockcroft‑Gault), hepatic panel, and any other organ function tests
- Documentation of prior therapies and evidence of progression on first‑line somatostatin analogues when applicable
- Planned Lutathera dosing schedule (dates) and documentation of intent to adhere to FDA regimen (maximum 4 doses)
- Statement of clinician qualifications to administer radiopharmaceuticals and informed consent documentation
Place in Therapy and Treatment Sequence
Position Lutathera appropriately in the treatment sequence. For SSTR‑positive inoperable locally advanced or metastatic GEP‑NETs, PRRT is generally considered after progression on first‑line somatostatin analogues; alternative second‑line options should be documented when applicable. For certain situations (per NCCN) Lutathera may be considered earlier (e.g., selected pancreatic or midgut NETs with Ki‑67 ≥10%), but the prior authorization must reflect the stated indication and supporting evidence.
- Consider PRRT after progression on first‑line somatostatin analogues (octreotide/lanreotide) for inoperable locally advanced or metastatic GEP‑NETs
- Document alternatives and rationale if Lutathera is chosen over second‑line comparators (chemotherapy, everolimus, hepatic‑directed therapy)
- If used as first‑line in specific high‑risk presentations (per NCCN), provide documentation supporting that decision
Prior Treatment Considerations and Comparator Therapies
Prior treatment considerations and comparator therapies must be documented. List prior or considered systemic and locoregional therapies (e.g., everolimus, temozolomide, capecitabine/temozolomide, hepatic embolization, external beam radiation) and note if iobenguane I‑131 was considered for MIBG‑positive pheochromocytoma/paraganglioma. Clinical trial participation should be discussed and preferred when appropriate.
- Document prior use or consideration of comparator therapies (everolimus, temozolomide, capecitabine, cytotoxic regimens, hepatic‑directed therapies)
- Consider iobenguane I‑131 for MIBG‑positive pheochromocytoma/paraganglioma as an alternative
- Encourage and document discussion of clinical trial options for rare indications
Definitions and Intended Populations
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analogue used as peptide receptor radionuclide therapy (PRRT). It binds somatostatin receptors on tumor cells, is internalized, and delivers beta radiation to induce tumor cell damage. Randomized controlled trial evidence supports benefit in treatment‑refractory gastroenteropancreatic neuroendocrine tumors, while evidence for other tumor types (bronchopulmonary, thymus, pheochromocytoma/paraganglioma) is limited and primarily derived from nonrandomized studies, registries, and case series; guideline bodies provide cautious, sometimes category 2A, recommendations for select non‑GEP indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.